Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.
In April, SyndicateRoom's Access EIS Fund invested in The Ova, a UK-based fertility supplement company, co-investing with one of our leading angel investors. You'll find more information about this company below.
The science-first approach
OVA has positioned itself as a leader in the fertility supplement space through its unwavering commitment to scientific evidence. Their products are backed by over 200 clinical studies, providing a level of credibility rarely seen in the supplement industry. Each formulation is created with therapeutic dosages of bioavailable ingredients, ensuring maximum efficacy for consumers.
The company's core mission revolves around improving reproductive health for would-be parents, "supporting from curiosity to conception and pregnancy to postpartum". This holistic approach to fertility care creates multiple revenue streams across the entire reproductive journey.
Manufacturing excellence
Quality control represents a significant competitive advantage for OVA. Their supplements are manufactured in FDA-approved facilities in the UK, adhering to strict safety and quality standards. This commitment to manufacturing excellence not only ensures product reliability but also builds consumer trust—a crucial factor in the sensitive fertility market.
Market opportunity
The fertility supplement market presents a substantial growth opportunity. With fertility issues affecting millions of couples worldwide and increasing awareness around reproductive health, demand for effective, science-backed solutions continues to rise.
Unlike many competitors who take advantage of vulnerable consumers with unsubstantiated claims, OVA has built its brand on transparency and clinical evidence. This ethical approach resonates strongly with today's informed consumers who increasingly seek products with proven efficacy.
Expert-led innovation
OVA's team includes fertility specialists, nutritionists, and scientific experts who continuously refine their formulations based on the latest clinical data. This expert-led approach enables the company to stay at the forefront of reproductive health innovation and quickly adapt to emerging research findings.
Investment potential
For investors, OVA represents an opportunity to enter the rapidly expanding fertility wellness sector with a company that differentiates itself through scientific credibility, manufacturing quality, and a comprehensive product range. The company's focus on bioavailable ingredients in therapeutic dosages creates barriers to entry for potential competitors.
As awareness of fertility issues continues to grow and more couples seek support on their reproductive journey, OVA is exceptionally well-positioned to capture market share and deliver strong returns. Their science-first, ethical approach provides a sustainable competitive advantage in an industry where trust is paramount.
With its roots firmly planted in clinical research and a clear mission to support reproductive health at every stage, OVA offers not just products, but scientifically-validated solutions—making it a fertile ground for investment growth.
The Access EIS Fund
Our fund co-invests with proven angel investors to build large portfolios of hand-picked companies for our investors. It's a high risk investment, and we can't guarantee that every startup will be a unicorn, but we're confident that our approach is the smartest on the market. Even better, we can show you the data to prove it.
If you're interested and would like to find out the benefits of investing towards the start of the tax year, you can call us on 01223 478 558 and we'll be happy to answer any questions you might have.
To be notified when the Access EIS Fund is next open to investment, click the button below to register with us.
